# OnCo record arx517 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/arx517/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "arx517" ;
  schema:name "ARX517"@en ;
  schema:alternateName "JNJ-95298177"@en ;
  schema:description "ARX517 is an experimental antibody-drug conjugate for metastatic prostate cancer, aimed at the protein PSMA. Ambrx developed it and Johnson & Johnson took it over when it bought Ambrx in 2024."@en ;
  schema:url <https://onco.cc/drugs/arx517/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04662580>, <https://clinicaltrials.gov/study/NCT07082920> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "deal-asset" ;
  onco:modality "Antibody-drug conjugate (PSMA, microtubule-disrupting payload)" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/psma/> ;
  onco:companies <https://onco.cc/companies/ambrx/>, <https://onco.cc/companies/johnson-johnson/> ;
  onco:trials <https://onco.cc/trials/nct04662580/> .